CARsgen Therapeutics, a private and venture backed company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, today provided a business and clinical update on its immunotherapy programs.
New Partnership Agreements
In September 2015, CARsgen and Shanghai Cancer Institute entered into a five year research and development agreement for the advancement of CARsgen's CAR-T cancer immunotherapeutics. The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies. Under terms of the agreement, CARsgen will own commercial rights of any intellectual assets generated from the collaboration. Financial terms of the agreement were not disclosed.
Armetheon and Lee's Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand